Novartis and Aurobindo canceled a billion-dollar deal
Novartis Aurobindo and jointly took the decision to withdraw from the deal worth 1 billion dollars. The agreement included the transfer of rights to Aurobindo 300 kinds of generic drugs, however, in the anticipated time frame has not been received the decision of the Antimonopoly Department of the USA, and that was the reason for […]